Which is worse: fructose-sweetened drinks or glucose-sweetened drinks? For some time, we have lacked consensus on the degree of punishment our bodies take from drinks sugared by these common saccharines. For now, fructose may again be wearing the crown, scoring unhealthy points in abdominal adiposity, and triglyceride and LDL levels, among other categories. Nutritional biologist Dr. Kimber Stanhope, from the University of California, Davis, joins host Dr. Larry Kaskel to shed some new light on this enduring debate. The lead author of a recent study published in the Journal of Clinical Investigation on the consumption of fructose-sweetened and glucose-sweetened beverages, Dr. Stanhope also explains that there is little value in directly applying these results to fruits, because fruits confer other important health benefits.
Weighing the Adverse Effects of Fructose vs. Glucose

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Which is worse: fructose-sweetened drinks or glucose-sweetened drinks? For some time, we have lacked consensus on the degree of punishment our bodies take from drinks sugared by these common saccharines. For now, fructose may again be wearing the crown, scoring unhealthy points in abdominal adiposity, and triglyceride and LDL levels, among other categories. Nutritional biologist Dr. Kimber Stanhope, from the University of California, Davis, joins host Dr. Larry Kaskel to shed some new light on this enduring debate. The lead author of a recent study published in the Journal of Clinical Investigation on the consumption of fructose-sweetened and glucose-sweetened beverages, Dr. Stanhope also explains that there is little value in directly applying these results to fruits, because fruits confer other important health benefits.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
M3: Managing the Cardiometabolic Risk in MASH
Cardiorenal Collaboration: Optimizing Multidisciplinary Care in the CvRM Patient
The Heart’s Aftermath: IRI’s Impact on Cardiac Morbidity & Mortality
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?